

Use of β_2 -adrenoreceptor agonist and antagonist drugs

Neurology

93, e135-e142

DOI: [10.1212/wnl.00000000000007694](https://doi.org/10.1212/wnl.00000000000007694)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Author response: Lower carotid revascularization rates after stroke in racial/ethnic minority-serving US hospitals. <i>Neurology</i> , 2020, 94, 897-897. | 1.5 | 0 |
| 2 | Beta Agonists and Progression of Parkinson's Disease in Older Adults: A Retrospective Cohort Study. <i>Movement Disorders</i> , 2020, 35, 1275-1277. | 2.2 | 2 |
| 3 | Reader response: Use of $\hat{\imath}^2$ -adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. <i>Neurology</i> , 2020, 94, 898-899. | 1.5 | 2 |
| 4 | $\hat{\imath}^2$ -Adrenoceptor Drugs and Parkinsonâ€™s Disease: A Nationwide Nested Caseâ€™Control Study. <i>CNS Drugs</i> , 2020, 34, 763-772. | 2.7 | 11 |
| 5 | The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinsonâ€™s Disease. <i>Biomolecules</i> , 2020, 10, 912. | 1.8 | 18 |
| 6 | Author response: Use of $\hat{\imath}^2$ -adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. <i>Neurology</i> , 2020, 94, 899-899. | 1.5 | 0 |
| 7 | Editors' note: Use of $\hat{\imath}^2$ -adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. <i>Neurology</i> , 2020, 94, 897-898. | 1.5 | 0 |
| 8 | $\hat{\imath}^2$ -adrenoreceptors and the risk of Parkinson's disease. <i>Lancet Neurology</i> , The, 2020, 19, 247-254. | 4.9 | 49 |
| 10 | Focused Ultrasound Thalamotomy for the Treatment of Essential Tremor: A 2-Year Outcome Study of Chinese People. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 697029. | 1.7 | 10 |
| 11 | The association between developing Parkinson's disease and $\hat{\imath}^2$ -Adrenoceptor acting agents use: A systematic review and meta-analysis. <i>Journal of the Neurological Sciences</i> , 2021, 430, 120009. | 0.3 | 4 |
| 12 | Risk Factors for Phenoconversion in <sc>Rapid Eye Movement</sc> Sleep Behavior Disorder. <i>Annals of Neurology</i> , 2022, 91, 404-416. | 2.8 | 27 |
| 13 | Slowing Parkinsonâ€™s Disease Progression with Vaccination and Other Immunotherapies. <i>CNS Drugs</i> , 2022, 36, 327-343. | 2.7 | 6 |
| 14 | Shared Molecular Targets in Parkinsonâ€™s Disease and Arterial Hypertension: A Systematic Review. <i>Biomedicines</i> , 2022, 10, 653. | 1.4 | 3 |
| 15 | Bioactive human Alzheimer brain soluble $\hat{\imath}^2$: pathophysiology and therapeutic opportunities. <i>Molecular Psychiatry</i> , 2022, 27, 3182-3191. | 4.1 | 14 |
| 16 | Beta-adrenergic drugs and risk of Parkinsonâ€™s disease: A systematic review and meta-analysis. <i>Ageing Research Reviews</i> , 2022, 80, 101670. | 5.0 | 6 |
| 17 | Identifying Protective Drugs for Parkinson's Disease in Healthâ€™Care Databases Using Machine Learning. <i>Movement Disorders</i> , 2022, 37, 2376-2385. | 2.2 | 6 |
| 18 | Association between use of $\hat{\imath}^2$ -adrenergic receptor agonists and incidence of Parkinsonâ€™s disease: Retrospective cohort analysis. <i>PLoS ONE</i> , 2022, 17, e0276368. | 1.1 | 2 |
| 19 | Alcohol and Parkinsonâ€™s Disease: A Systematic Review and Meta-Analysis. <i>Journal of Parkinson's Disease</i> , 2022, 12, 2369-2381. | 1.5 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 20 | Beta2-adrenoreceptor agonists and long-term risk of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2023, 110, 105389. | 1.1 | 2 |
| 21 | Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research. <i>Metabolic Brain Disease</i> , 2023, 38, 873-919. | 1.4 | 3 |
| 22 | Opposing effects of β -2 and β -1 adrenergic receptor signaling on neuroinflammation and dopaminergic neuron survival in α -synuclein-mediated neurotoxicity. <i>Journal of Neuroinflammation</i> , 2023, 20, . | 3.1 | 2 |
| 23 | β -Adrenoreceptor Agonists, Montelukast, and Parkinson Disease Risk. <i>Annals of Neurology</i> , 2023, 93, 1023-1028. | 2.8 | 2 |
| 25 | Locus Coeruleus and Noradrenergic Pharmacology in Neurodegenerative Disease. <i>Handbook of Experimental Pharmacology</i> , 2023, , . | 0.9 | 2 |